3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
5
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Small Cell Lung Carcinoma
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia, Myeloid, Acute
2
Carcinoma, Non-Small-Cell Lung
2
Recurrence
1
Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Hodgkin Disease
1
Carcinoma, Small Cell
1
Interventions
Rituximab
43
Cyclophosphamide
26
fludarabine
15
ibrutinib
14
Vincristine
11
Prednisone
11
Doxorubicin
11
pirtobrutinib
10
Bendamustine Hydrochloride
10
obinutuzumab
9
polatuzumab vedotin
6
Inotuzumab Ozogamicin
6
tocilizumab
5
pembrolizumab
5
glofitamab
5
Gemcitabine
5
zanubrutinib
4
venetoclax
4
ublituximab
4
Lenalidomide
4
Brentuximab Vedotin
4
Antigens, CD19
4
tazemetostat
3
acalabrutinib
3
Everolimus
3
DTRMWXHS-12
3
veltuzumab
2
sepantronium
2
iberdomide
2
denileukin diftitox
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, B-Cell
×
etoposide phosphate
×
Clear all
NCT06230224
2026-05-11
OLYMPIA-4
Regeneron Pharmaceuticals
Phase 3
Active not recruiting
216 enrolled